

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.



Alebund Pharmaceuticals (Jiangsu) Limited
禮邦醫藥(江蘇)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 09637)

NOTICE OF EXTRAORDINARY GENERAL MEETING

NOTICE IS HEREBY GIVEN that an extraordinary general meeting (the “EGM”) of Alebund Pharmaceuticals (Jiangsu) Limited (the “**Company**”) will be held at 10:00 a.m. on Friday, August 14, 2026 at Meeting Room 303, 1206, Hong Kong Plaza South Building, No.283, Middle Huaihai Road, Huangpu District, Shanghai, PRC, or any adjournment thereof, for the purpose of considering and, if thought fit, passing with or without amendments, the following resolutions of the Company. Unless otherwise indicated, capitalised terms used in this notice shall have the same meanings as those defined in the circular of the Company dated July 24, 2026.

ORDINARY RESOLUTION

1. To consider and approve the appointment of Ernst & Young as the auditor of the Company for a term commencing from the date of passing of this resolution until the conclusion of the next annual general meeting of the Company, and to authorise the Board to fix its remuneration.

SPECIAL RESOLUTIONS

2. To consider and approve the granting of a general mandate to the Board to exercise the power of the Company to allot, issue and/or deal with additional Shares and/or sell or transfer Treasury Shares of the Company:

“THAT:

- (a) subject to paragraphs (c) and (d) below and in accordance with the Listing Rules, the Company Law of the PRC, other applicable laws and regulations and the Articles of Association, a general and unconditional mandate be and is hereby granted to the Board during the Relevant Period (as defined below) to exercise, once or more, all powers of the Company to allot, issue and/or deal with additional Shares and/or sell or transfer Treasury Shares of the Company, if any, and to make or grant offers, agreements and options which would or might require the exercise of such powers;

- (b) the mandate under paragraph (a) above shall authorise the Board during the Relevant Period to make or grant offers, agreements and options which would or might require Shares to be allotted, issued and/or dealt with, or Treasury Shares to be sold or transferred, after the end of the Relevant Period;
- (c) the aggregate number of Shares allotted, issued and/or dealt with, and Treasury Shares sold or transferred, by the Board pursuant to the mandate under paragraph (a) above shall not exceed 20% of the total number of Shares in issue (excluding Treasury Shares, if any) as at the date of passing of this resolution, except for Shares which may be allotted, issued or dealt with pursuant to conversion of capital reserve into capital in accordance with the Company Law of the PRC and the Articles of Association;
- (d) the Board shall exercise the mandate under paragraph (a) above in compliance with the Listing Rules, the Company Law of the PRC, other applicable PRC laws and regulations and, where applicable, the requirements and approvals of the Stock Exchange, the China Securities Regulatory Commission and other relevant regulatory authorities;
- (e) for the purpose of this resolution, “Relevant Period” means the period from the date of passing of this resolution until whichever is the earliest of: (i) the conclusion of the next annual general meeting of the Company; (ii) the expiration of the period within which the next annual general meeting of the Company is required to be held under the Articles of Association or applicable laws and regulations; or (iii) the date on which the powers granted under this resolution are revoked or varied by a special resolution of the Shareholders in general meeting;
- (f) subject to the relevant approvals of the relevant authorities (if required) and the exercise of the powers granted under paragraph (a) above in accordance with applicable laws and regulations, the Board be and is hereby authorised to increase the registered capital of the Company to reflect the number of Shares allotted and issued upon the exercise of the powers granted under paragraph (a) above, provided that the registered capital of the Company shall not exceed 120% of the registered capital of the Company as at the date of passing of this resolution; and
- (g) the Board be and is hereby authorised to make such amendments to the Articles of Association as it considers appropriate and necessary to reflect any change in the share capital structure of the Company arising from the exercise of the powers granted under paragraph (a) above, and to handle related approval, registration and filing procedures.”

3. To consider and approve the granting of a general mandate to the Board to repurchase H Shares:

“THAT:

- (a) subject to paragraphs (b) and (c) below and in accordance with the Listing Rules, the Company Law of the PRC, other applicable laws and regulations and the Articles of Association, a general mandate be and is hereby granted to the Board during the Repurchase Mandate Period (as defined below) to exercise all powers of the Company to repurchase H Shares on the Stock Exchange on such terms and conditions as the Board may determine;
- (b) the total number of H Shares which may be repurchased by the Company pursuant to the mandate under paragraph (a) above shall not exceed 10% of the total number of H Shares in issue (excluding Treasury Shares, if any) as at the date of passing of this resolution;
- (c) the Board shall exercise the mandate under paragraph (a) above in compliance with the Listing Rules, the Company Law of the PRC, other applicable PRC laws and regulations and, where applicable, the requirements and approvals of the Stock Exchange, the Securities and Futures Commission of Hong Kong, the China Securities Regulatory Commission and other relevant regulatory authorities;
- (d) the Board be and is hereby authorised to formulate, implement, suspend or terminate specific plans for the repurchase of H Shares, including but not limited to determining the timing, price and number of H Shares to be repurchased;
- (e) subject to the Listing Rules and applicable laws and regulations, the Board be and is hereby authorised to cancel the H Shares repurchased and reduce the registered capital of the Company, make corresponding amendments to the Articles of Association, notify the creditors of the Company, publish announcements, handle statutory registrations and filings, and/or hold the repurchased H Shares as Treasury Shares;
- (f) the Board be and is hereby authorised to handle all other matters in connection with the repurchase of H Shares, except for matters which must be exercised by the Shareholders in general meeting under applicable laws, regulations, the Listing Rules or the Articles of Association; and
- (g) for the purpose of this resolution, “Repurchase Mandate Period” means the period from the date of passing of this resolution until the earliest of: (i) the conclusion of the next annual general meeting of the Company; (ii) the expiration of the period within which the next annual general meeting of the Company is required to be held

under the Articles of Association or applicable laws and regulations; or (iii) the date on which the mandate granted under this resolution is revoked or varied by a special resolution of the Shareholders in general meeting.”

Details of the above resolutions proposed at the EGM are contained in the circular of the Company dated July 24, 2026, which is available on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.alebund.com).

By order of the Board
Alebund Pharmaceuticals (Jiangsu) Limited
Dr. Gavin Guoyao Xia
*Chairman of the Board, executive Director and
Chief Executive Officer*

Hong Kong, Friday, July 24, 2026

As at the date of this notice, the Board comprises: Dr. Gavin Guoyao Xia, Jin Tian, M.D., Ms. Wang Yun and Dr. Zhang Huading as executive Directors; Dr. Lu An as non-executive Director; and Dr. Xu Runhong, Dr. Zhui Chen and Mr. Leung Chi Wai as independent non-executive Directors.

Notes:

1. Resolution to be submitted at the EGM shall be voted on by poll.
2. The record date for the purpose of ascertaining the eligibility of the holders of H Shares and Unlisted Shares to attend and vote at the EGM is on Friday, August 14, 2026. In order to ascertain holders of H Shares who are entitled to attend the EGM, the register of members of holders of H Shares will be closed from Tuesday, August 11, 2026 to Friday, August 14, 2026 (both days inclusive). Holders of H Shares who intend to attend the EGM are required to lodge all completed transfer documents accompanied by the relevant share certificates with the Company's H Share registrar, Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong on or before 4:30 p.m. on Monday, August 10, 2026 for registration. Holders of Unlisted Shares who intend to attend the EGM are required to lodge all completed transfer documents accompanied by the relevant share certificates at the office of the Company, at Meeting Room 303, 1206, Hong Kong Plaza South Building, No.283, Middle Huaihai Road, Huangpu District, Shanghai, PRC on or before 10:00 a.m. on Friday, August 14, 2026 for registration.
3. Shareholders who are entitled to attend and vote at the EGM may appoint one or more proxies to attend and vote on their behalf. A proxy need not be a Shareholder. If more than one proxy is appointed, the number and class of Shares in respect of which each such proxy is so appointed shall be specified in the appointment of the proxy.
4. The form of proxy must be signed by the Shareholder or by an authorised person appointed by the Shareholder in writing. If the Shareholder is a legal person, it must be stamped with the seal of the legal person or signed by a director or duly authorised attorney. If the form is signed by an attorney of the Shareholder, the power of attorney authorising that attorney to sign or other authorisation document must be notarised.

5. In order to be valid, the form of proxy, and if the form of proxy is signed by a person under a power of attorney or other authorisation document on behalf of the appointor, a notarially certified copy of that power of attorney or other authorisation document, must be deposited with (i) the H Share registrar of the Company, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong (for holders of H Shares); or (ii) the office of the Company, at Meeting Room 303, 1206, Hong Kong Plaza South Building, No.283, Middle Huaihai Road, Huangpu District, Shanghai, PRC (for holders of Unlisted Shares), not less than 24 hours before the time appointed for holding the EGM or any adjournment thereof.

In case of joint holders of any Shares, any one of the joint holders can vote on such Shares at the EGM in person or by proxy as if he/she is the only holder entitled to vote. If more than one joint holders attend the EGM in person or by proxy, only the vote of the person whose name appears first in the register of members of the Company relating to such Shares will be accepted as the sole and exclusive vote of the joint holders.

Completion and return of the form of proxy will not preclude a Shareholder from attending and voting in person at the EGM or any adjournment thereof should he/she/it so wish. In this case, the power of attorney will be deemed to have been revoked.

6. Shareholders and their proxies are required to produce identity proof when attending the EGM (and any adjournment thereof).
7. The EGM is expected to last for no more than half a day. Shareholders or their proxies attending the EGM are responsible for their own transportation and accommodation expenses.
8. All times refer to Hong Kong local time, except as otherwise stated.